Catalog No.S1760 Synonyms: MDL473
Molecular Weight(MW): 877.03
Rifapentine is an antibiotic, which inhibits DNA-dependent RNA polymerase activity, used to treat tuberculosis.
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
|Description||Rifapentine is an antibiotic, which inhibits DNA-dependent RNA polymerase activity, used to treat tuberculosis.|
Rifapentine inhibits the function of DNA-dependent RNA polymerase in strains of M. tuberculosis, while inducing no effect on mammalian cells. Both Rifapentine and its active metabolite, 25-desacetylrifapentine, localize within monocyte-derived macrophages, thus allowing for intracellular inhibition of M. tuberculosis at a greater kill rate as compared with that of the parent or metabolite alone. Rifapentine is deacetylated in the liver and induces cytochrome P450 much less than rifampin.  Rifapentine has shown higher bacteriostatic and bactericidal activities (MICs and MBCs) than RMP, especially against intracellular bacteria growing in human monocyte-derived macrophages. 
|In vivo||Rifapentine inhibits bacterial RNA synthesis by binding to the β-subunit of DNA-dependent RNA polymerase in susceptible species. Rifapentine is generally more active than rifampicin against sensitive strains of M. tuberculosis.  Rifapentine significantly increases the rate of antipyrine and pentobarbital metabolism in vivo. Rifapentine also increases liver weight, the content of liver microsomal protein and cytochrome P-450, the activity of NADPH-cytochrome C reductase and NADPH oxidase.  Rifapentine combined with isoniazid (INH) and pyrazinamide (PZA) administered daily results in an apparent clearance of M.tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. |
-  Temple ME, et al. Ann Pharmacother, 1999, 33(11), 1203-1210.
-  Mor N, et al. Antimicrob Agents Chemother, 1995, 39(9), 2073-2077.
-  Jarvis B, et al. Drugs, 1998, 56(4), 607-616.
|In vitro||DMSO||100 mg/mL (114.02 mM)|
|Ethanol||17 mg/mL (19.38 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04094012||Not yet recruiting||Drug: isoniazid and rifapentine||Latent Tuberculosis Infection||National Taiwan University Hospital||October 1 2019||Phase 3|
|NCT03730181||Not yet recruiting||Drug: Rifapentine|Drug: Isoniazid||Latent Tuberculosis||Centers for Disease Control and Prevention|University of Stellenbosch|Johns Hopkins University|Sanofi|University of Cape Town|Chris Hani Baragwanath Academic Hospital|Washington D.C. Veterans Affairs Medical Center||September 2019||Phase 1|Phase 2|
|NCT01690403||Completed||Drug: rifapentine (M000473)|Drug: EFZ EMT TDF||Tuberculosis||Sanofi||December 2012||Phase 1|
|NCT01574638||Completed||Drug: Rifapentine (RPT)||Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||June 2012||Phase 1|
|NCT00814671||Completed||Drug: Rifapentine 450|Drug: Rifapentine 600|Drug: Rifampin||Tuberculosis||Johns Hopkins University|University of Cape Town Lung Institute|University of Cape Town||April 2010||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.